Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Acquired by Perceptive Advisors LLC

Perceptive Advisors LLC grew its holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 50.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,007,367 shares of the company’s stock after buying an additional 338,208 shares during the quarter. Perceptive Advisors LLC’s holdings in Tyra Biosciences were worth $16,108,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Kynam Capital Management LP purchased a new position in Tyra Biosciences in the 4th quarter valued at approximately $4,712,000. Wellington Management Group LLP increased its stake in Tyra Biosciences by 8.8% in the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after purchasing an additional 8,324 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in Tyra Biosciences in the 1st quarter valued at approximately $977,000. Vanguard Group Inc. increased its stake in Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after purchasing an additional 140,833 shares in the last quarter. Finally, BVF Inc. IL increased its stake in Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after purchasing an additional 1,921,599 shares in the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Thursday, August 8th. Piper Sandler started coverage on Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. Finally, Oppenheimer lifted their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $26.40.

Insider Activity at Tyra Biosciences

In related news, CEO Todd Harris sold 10,092 shares of Tyra Biosciences stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $24.13, for a total value of $243,519.96. Following the transaction, the chief executive officer now owns 1,479,528 shares in the company, valued at $35,701,010.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have sold 16,390 shares of company stock worth $396,444. 15.40% of the stock is owned by insiders.

Tyra Biosciences Stock Down 0.3 %

Shares of NASDAQ:TYRA opened at $23.34 on Monday. The company has a market cap of $1.23 billion, a P/E ratio of -13.89 and a beta of 1.01. Tyra Biosciences, Inc. has a 52 week low of $10.38 and a 52 week high of $25.14. The business has a fifty day simple moving average of $21.62 and a 200-day simple moving average of $18.86.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. Sell-side analysts expect that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.